CY1118551T1 - Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 - Google Patents
Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4Info
- Publication number
- CY1118551T1 CY1118551T1 CY20171100010T CY171100010T CY1118551T1 CY 1118551 T1 CY1118551 T1 CY 1118551T1 CY 20171100010 T CY20171100010 T CY 20171100010T CY 171100010 T CY171100010 T CY 171100010T CY 1118551 T1 CY1118551 T1 CY 1118551T1
- Authority
- CY
- Cyprus
- Prior art keywords
- dll4
- methods
- disorders
- diseases
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Zoology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση παρέχει μεθόδους θεραπείας μιας νόσου ή διαταραχής, στην οποία η αύξηση του αριθμού των ρυθμιστικών κυττάρων Τ (Treg) είναι ευεργετικός, μέσω της χορήγησης σε ένα υποκείμενο που πάσχει από μια τέτοια νόσο ή διαταραχή μιας θεραπευτικά αποτελεσματικής ποσότητας ανταγωνιστών του Dll4 που αποκλείουν τις οδούς σήματος Dll4-Notch, αυξάνοντας έτσι τον αριθμό των Treg. Οι νόσοι ή οι διαταραχές που δύνανται να θεραπευτούν με τις μεθόδους της εφεύρεσης περιλαμβάνουν αυτοάνοσες νόσους ή διαταραχές, όπως σκλήρυνση κατά πλάκας (ΣΚΠ), διαβήτη και συναφείς. Οι κατάλληλοι ανταγωνιστές του Dll4 για την εφεύρεση περιλαμβάνουν αντισώματα ή θραύσματα αντισωμάτων που δεσμεύουν ειδικά τον Dll4 και παρεμποδίζουν τις αλληλεπιδράσεις Dll4-Notch, τον εξωκυτταρικό τομέα του Dll4, και τα συναφή. Η εφεύρεση παρέχει επίσης μεθόδους πρόληψης της εκδήλωσης ή της υποτροπής τέτοιων νόσων ή διαταραχών σε ένα υποκείμενο που έχει προδιάθεση ή ευπάθεια να παρουσιάσει τέτοιες νόσους ή διαταραχές. Επιπλέον, οι μέθοδοι της εφεύρεσης είναι χρήσιμες στη θεραπεία ή στην πρόληψη των απορρίψεων οργάνων μεταμόσχευσης ή της νόσου μοσχεύματος έναντι του ξενιστή.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29980110P | 2010-01-29 | 2010-01-29 | |
| US36168710P | 2010-07-06 | 2010-07-06 | |
| US38869710P | 2010-10-01 | 2010-10-01 | |
| PCT/US2011/022810 WO2011094465A1 (en) | 2010-01-29 | 2011-01-28 | Methods of treating autoimmune diseases with dll4 antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118551T1 true CY1118551T1 (el) | 2017-07-12 |
Family
ID=43925413
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101167T CY1118223T1 (el) | 2010-01-29 | 2016-11-14 | Μεθοδοι θεραπειας του διαβητη με ανταγωνιστες toy dll4 |
| CY20171100010T CY1118551T1 (el) | 2010-01-29 | 2017-01-04 | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101167T CY1118223T1 (el) | 2010-01-29 | 2016-11-14 | Μεθοδοι θεραπειας του διαβητη με ανταγωνιστες toy dll4 |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US8889133B2 (el) |
| EP (2) | EP2528945B1 (el) |
| JP (2) | JP5997613B2 (el) |
| KR (2) | KR101797918B1 (el) |
| CN (2) | CN102947336B (el) |
| AR (1) | AR080026A1 (el) |
| AU (2) | AU2011210771B2 (el) |
| BR (2) | BR112012018766A2 (el) |
| CA (2) | CA2787615C (el) |
| CY (2) | CY1118223T1 (el) |
| DK (2) | DK2528945T3 (el) |
| ES (2) | ES2605430T3 (el) |
| HR (2) | HRP20170130T1 (el) |
| HU (2) | HUE031432T2 (el) |
| IL (2) | IL220887A (el) |
| JO (2) | JO3183B1 (el) |
| LT (2) | LT2528945T (el) |
| MX (2) | MX343555B (el) |
| MY (2) | MY156538A (el) |
| PL (2) | PL2528946T3 (el) |
| PT (2) | PT2528945T (el) |
| RS (2) | RS55595B1 (el) |
| RU (2) | RU2587620C2 (el) |
| SG (4) | SG182527A1 (el) |
| SI (2) | SI2528945T1 (el) |
| SM (2) | SMT201600412B (el) |
| TW (2) | TWI564019B (el) |
| UY (1) | UY33206A (el) |
| WO (2) | WO2011094467A2 (el) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP3029070A1 (en) | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Therapeutic dll4 binding proteins |
| DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| EP3680253A3 (en) | 2010-03-02 | 2020-09-30 | AbbVie Inc. | Therapeutic dll4 binding proteins |
| US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
| KR101535341B1 (ko) * | 2012-07-02 | 2015-07-13 | 한화케미칼 주식회사 | Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도 |
| NZ707641A (en) | 2012-11-01 | 2016-09-30 | Abbvie Inc | Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof |
| TW201438736A (zh) * | 2012-11-14 | 2014-10-16 | Regeneron Pharma | 以ｄｌｌ４拮抗劑治療卵巢癌之方法 |
| CA2917402C (en) | 2013-07-09 | 2019-10-22 | Hanwha Chemical Corporation | Novel dual-targeting protein binding specifically to dll4 and vegf and use thereof |
| CN111239415B (zh) * | 2013-10-17 | 2024-03-26 | 综合医院公司 | 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物 |
| CN106459971B (zh) * | 2014-04-08 | 2019-08-16 | 弗劳恩霍夫应用研究促进协会 | 用于治疗自身免疫性疾病的联合疗法 |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| US11446262B2 (en) | 2018-11-29 | 2022-09-20 | Debora Zucco Sassi Yonezawa Siviglia | Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination |
| EP3886856A4 (en) * | 2018-11-29 | 2022-01-19 | Zucco Sassi Yonezawa Siviglia, Debora | METHOD FOR TREATING OR PREVENTING SEIZURES ASSOCIATED WITH AN EPILEPTIC DISORDER |
| US20240287173A1 (en) * | 2021-03-30 | 2024-08-29 | National University Corporation Kumamoto University | Therapeutic agent for muscular atrophy |
| WO2023159166A1 (en) * | 2022-02-18 | 2023-08-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| CA2486712C (en) * | 2002-05-21 | 2012-01-03 | Cv Therapeutics, Inc. | Method of treating diabetes |
| WO2005103081A2 (en) | 2004-04-20 | 2005-11-03 | Genmab A/S | Human monoclonal antibodies against cd20 |
| US20060134121A1 (en) | 2004-10-29 | 2006-06-22 | Gavin Thurston | DII4 antagonists, assays, and therapeutic methods thereof |
| US20080107648A1 (en) * | 2005-12-16 | 2008-05-08 | Regeneron Pharmaceuticals, Inc. | Therapeutic methods for inhibiting tumor growth with DII4 antagonists |
| PL2041177T3 (pl) | 2006-06-02 | 2012-09-28 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| JP2009539384A (ja) * | 2006-06-06 | 2009-11-19 | ジェネンテック・インコーポレーテッド | 抗ｄｌｌ４抗体および抗ｄｌｌ４抗体使用の方法 |
| US20080014196A1 (en) | 2006-06-06 | 2008-01-17 | Genentech, Inc. | Compositions and methods for modulating vascular development |
| BRPI0716424B8 (pt) * | 2006-08-07 | 2021-05-25 | Regeneron Pharma | uso do antagonista de ligante delta-like 4 (dll4) |
| BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
| NO347649B1 (no) * | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| EP3029070A1 (en) * | 2009-08-29 | 2016-06-08 | AbbVie Inc. | Therapeutic dll4 binding proteins |
| JO3183B1 (ar) * | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
-
2011
- 2011-01-23 JO JOP/2011/0021A patent/JO3183B1/ar active
- 2011-01-26 AR ARP110100250A patent/AR080026A1/es unknown
- 2011-01-28 SM SM201600412T patent/SMT201600412B/it unknown
- 2011-01-28 LT LTEP11701735.0T patent/LT2528945T/lt unknown
- 2011-01-28 PL PL11701933T patent/PL2528946T3/pl unknown
- 2011-01-28 RU RU2012136816/10A patent/RU2587620C2/ru not_active IP Right Cessation
- 2011-01-28 WO PCT/US2011/022817 patent/WO2011094467A2/en active Application Filing
- 2011-01-28 MY MYPI2012003169A patent/MY156538A/en unknown
- 2011-01-28 CA CA2787615A patent/CA2787615C/en active Active
- 2011-01-28 HU HUE11701933A patent/HUE031432T2/en unknown
- 2011-01-28 EP EP11701735.0A patent/EP2528945B1/en active Active
- 2011-01-28 WO PCT/US2011/022810 patent/WO2011094465A1/en active Application Filing
- 2011-01-28 DK DK11701735.0T patent/DK2528945T3/en active
- 2011-01-28 SG SG2012052049A patent/SG182527A1/en unknown
- 2011-01-28 US US13/015,652 patent/US8889133B2/en active Active
- 2011-01-28 DK DK11701933.1T patent/DK2528946T3/en active
- 2011-01-28 TW TW100103219A patent/TWI564019B/zh not_active IP Right Cessation
- 2011-01-28 CN CN201180016820.4A patent/CN102947336B/zh not_active Expired - Fee Related
- 2011-01-28 ES ES11701735.0T patent/ES2605430T3/es active Active
- 2011-01-28 BR BR112012018766A patent/BR112012018766A2/pt active Search and Examination
- 2011-01-28 ES ES11701933.1T patent/ES2609663T3/es active Active
- 2011-01-28 CN CN2011800165511A patent/CN102884081A/zh active Pending
- 2011-01-28 PT PT117017350T patent/PT2528945T/pt unknown
- 2011-01-28 MX MX2012008638A patent/MX343555B/es active IP Right Grant
- 2011-01-28 SG SG2012052056A patent/SG182528A1/en unknown
- 2011-01-28 RU RU2012136817/10A patent/RU2587624C2/ru not_active IP Right Cessation
- 2011-01-28 MX MX2012008740A patent/MX343553B/es active IP Right Grant
- 2011-01-28 KR KR1020127022496A patent/KR101797918B1/ko active IP Right Grant
- 2011-01-28 PL PL11701735T patent/PL2528945T3/pl unknown
- 2011-01-28 LT LTEP11701933.1T patent/LT2528946T/lt unknown
- 2011-01-28 KR KR1020127022506A patent/KR101832118B1/ko active IP Right Grant
- 2011-01-28 JP JP2012551293A patent/JP5997613B2/ja active Active
- 2011-01-28 JP JP2012551294A patent/JP5883801B2/ja active Active
- 2011-01-28 TW TW105101963A patent/TWI600433B/zh not_active IP Right Cessation
- 2011-01-28 HU HUE11701735A patent/HUE032985T2/en unknown
- 2011-01-28 RS RS20170036A patent/RS55595B1/sr unknown
- 2011-01-28 EP EP11701933.1A patent/EP2528946B1/en active Active
- 2011-01-28 AU AU2011210771A patent/AU2011210771B2/en active Active
- 2011-01-28 BR BR112012018820A patent/BR112012018820A8/pt not_active Application Discontinuation
- 2011-01-28 SI SI201131011A patent/SI2528945T1/sl unknown
- 2011-01-28 SI SI201131020A patent/SI2528946T1/sl unknown
- 2011-01-28 PT PT117019331T patent/PT2528946T/pt unknown
- 2011-01-28 SG SG10201500416RA patent/SG10201500416RA/en unknown
- 2011-01-28 US US13/015,637 patent/US8765125B2/en active Active
- 2011-01-28 AU AU2011210773A patent/AU2011210773B2/en active Active
- 2011-01-28 RS RS20170142A patent/RS55715B1/sr unknown
- 2011-01-28 MY MYPI2012003168A patent/MY156353A/en unknown
- 2011-01-28 UY UY0001033206A patent/UY33206A/es not_active Application Discontinuation
- 2011-01-28 CA CA2787394A patent/CA2787394C/en active Active
- 2011-01-28 SG SG10201500404QA patent/SG10201500404QA/en unknown
-
2012
- 2012-07-11 IL IL220887A patent/IL220887A/en not_active IP Right Cessation
- 2012-07-11 IL IL220889A patent/IL220889A/en not_active IP Right Cessation
-
2014
- 2014-05-22 US US14/285,409 patent/US20140255429A1/en not_active Abandoned
-
2016
- 2016-11-14 CY CY20161101167T patent/CY1118223T1/el unknown
-
2017
- 2017-01-04 CY CY20171100010T patent/CY1118551T1/el unknown
- 2017-01-16 SM SM201700021T patent/SMT201700021B/it unknown
- 2017-01-26 HR HRP20170130TT patent/HRP20170130T1/hr unknown
- 2017-02-16 HR HRP20170249TT patent/HRP20170249T1/hr unknown
- 2017-03-19 JO JOP/2017/0065A patent/JO3242B1/ar active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118551T1 (el) | Μεθοδοι θεραπειας αυτοανοσων νοσων με ανταγωνιστες του dll4 | |
| CY1119994T1 (el) | Συνθεσεις και μεθοδοι για αυξηση της μυϊκης μαζας και της μυϊκης δυναμης ανταγωνιζοντας ειδικα ton gdf8 και/ή την ακτιβινη α | |
| CY1121796T1 (el) | Συνθεσεις μονοσθενεις για δεσμευση cd28 και μεθοδοι χρησης | |
| JOP20200237A1 (ar) | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها | |
| CY1120665T1 (el) | Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους | |
| CY1120626T1 (el) | Αντισωματα και αλλα μορια που δεσμευουν β7-η1 και pd-1 | |
| CY1122476T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (τfρι) | |
| PE20141548A1 (es) | Anticuerpo anti-alfabeta tcr | |
| EA201391735A1 (ru) | Cd3-связывающие молекулы, способные к связыванию с cd3 человека и cd3, не являющимся человеческим | |
| EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
| NZ706377A (en) | Il-6 antagonists and uses thereof | |
| CY1115572T1 (el) | Αντι cxcr4 αντισωματα και χρηση αυτων για τη θεραπεια καρκινου | |
| EA201290589A1 (ru) | Cd127-связывающие белки | |
| EA201591113A1 (ru) | Антитела против антигена 2 дендритных клеток крови и их применение | |
| EA201070730A1 (ru) | Гуманизированные антитела, специфичные к фактору фон виллебранда | |
| CY1115349T1 (el) | Εξανθρωπισμενα αντι cxcr4 αντισωματα για τη θεραπεια καρκινου | |
| CY1123926T1 (el) | Αντισωματα κατα της τρανσγλουταμινασης 2 | |
| EA202191666A1 (ru) | Антитела к il-27 и их применение | |
| EA202091569A1 (ru) | Моноклональные антитела и способы их применения | |
| CY1123519T1 (el) | Ανθρωπινα μονοκλωνικα αντισωματα εξουδετερωσης il-ß | |
| MX2016008520A (es) | Anticuerpo bdca-2 antihumano novedoso. | |
| BR112014008331A2 (pt) | anticorpos sema4a anti-humanos úteis para tratar doença | |
| EA201790437A1 (ru) | Антигенсвязывающие белки, связывающиеся с cxcr3 | |
| EA201391453A1 (ru) | Новое антитело против рецептора il-23 человека | |
| PH12019500482A1 (en) | Antibody for treating autoimmune diseases |